PRINCETON, NJ, USA & TOKYO, Japan I March 31, 2025 I Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd.

P3 Health Partners' Q4 2024 earnings show 18% annual revenue growth and reaffirmed profitability goals for 2025.

By the same token, we find that a reasonably large percentage of patients who have ongoing proteinuria do so because they've accrued chronic damage with nephron loss. Chronic damage with nephron ...

AirSculpt Technologies, Inc. (NASDAQ: AIRS) Q4 2024 Earnings Call Transcript March 14, 2025 AirSculpt Technologies, Inc. misses on earnings expectations. Reported EPS is $-0.08 EPS, expectations were ...

For the most part, this is a haemodynamic effect which does not lead to nephron loss. Beyond a tight ARAS (probably at least 75%, see discussion below), GFR becomes proportional to systemic blood ...

Calcium level is regulated by parathyroid hormone (PTH), which increases calcium resorption from the bone and from the distal part of the nephron. PTH raises intestinal ... aquaporin may cause ...